GenSight Biologics S.A. (EPA:SIGHT)
0.0885
+0.0018 (2.08%)
Apr 2, 2026, 5:35 PM CET
GenSight Biologics Employees
GenSight Biologics had 13 employees as of June 30, 2025.
Employees
13
Change
n/a
Growth
n/a
Revenue / Employee
€50,154
Profits / Employee
€925,846
Market Cap
20.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 13 | - | - | 13 | 0 |
| Dec 31, 2024 | 16 | 0 | - | 16 | 0 |
| Dec 31, 2023 | 16 | -29 | -64.44% | 16 | 0 |
| Dec 31, 2022 | 45 | 7 | 18.42% | 45 | 0 |
| Dec 31, 2021 | 38 | 13 | 52.00% | 38 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsGenSight Biologics News
- 19 hours ago - GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates - Business Wire
- 8 days ago - GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025 - Business Wire
- 15 days ago - The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® - Business Wire
- 26 days ago - GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study - Business Wire
- 6 weeks ago - GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments - Business Wire
- 7 weeks ago - The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study - Business Wire
- 2 months ago - GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026 - Business Wire
- 3 months ago - GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates - Business Wire